Literature DB >> 7030200

Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations.

G C Armstrong, R Wise, R M Brown, J Hancox.   

Abstract

Eight healthy male volunteers received 1 g of either ceftazidime or cefamandole as an intravenous infection. Serial blood samples were taken over the next 8 h. Urine samples were collected over 24 h. Levels of these antibiotics were measured in the fluid of blisters resulting from application of cantharides. The concentration of ceftazidime in serum at 0.25 h after intravenous injection was 83.3 micrograms/ml. The serum half-lives for the respective drugs were 1.8 and 0.8 h. The mean apparent volume of distribution of ceftazidime (13.6 liters) was greater than that of cefamandole (9.8 liters). Plasma clearance was 111 ml/min for ceftazidime and 216 ml/min for cefamandole. The maximum blister fluid concentration of ceftazidime was 45.9 micrograms/ml, and that of cefamandole was 22.1 micrograms/ml. The relative availability of each drug in blister fluid compared with serum was similar.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7030200      PMCID: PMC181700          DOI: 10.1128/AAC.20.3.356

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Some physico-chemical factors in drug action.

Authors:  B B BRODIE; C A HOGBEN
Journal:  J Pharm Pharmacol       Date:  1957-06       Impact factor: 3.765

3.  Clinical pharmacology of cefamandole as compared with cephalothin.

Authors:  I W Fong; E D Ralph; E R Engelking; W M Kirby
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

4.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

5.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

6.  Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

  6 in total
  8 in total

1.  Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.

Authors:  Stefan Hajdu; Johannes Holinka; Sonja Reichmann; Alexander M Hirschl; Wolfgang Graninger; Elisabeth Presterl
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

2.  Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.

Authors:  M T Borin; G S Hughes; C R Spillers; R K Patel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 3.  Cephalosporins in gram-positive infections.

Authors:  J Symonds; A M Geddes
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.

Authors:  D Kalman; S L Barriere; B L Johnson
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

5.  Pharmacokinetics of cefpiramide (SM-1652) in humans.

Authors:  K Nakagawa; M Koyama; H Matsui; C Ikeda; K Yano; N Nakatsuru; K Yoshinaga; T Noguchi
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

6.  Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; C B Landersdorfer; S J Hüttner; G L Drusano; M Kinzig; U Holzgrabe; U Stephan; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

8.  Ceftazidime as single-agent therapy for gram-negative aerobic bacillary osteomyelitis.

Authors:  M C Bach; D M Cocchetto
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.